Molecular Oncology
Volume 4, Issue 2 , Pages 161-168 , April 2010

Aberrations of ERBB2 and TOP2A genes in breast cancer

  • Kirsten Vang Nielsen

      Affiliations

    • Dako A/S, Glostrup, Denmark
    • Corresponding Author InformationCorresponding author at: Produktionsvej 42, DK-2600 Glostrup, Denmark. Tel.: +45 4485 9494.
    • ,
  • Sven Müller

      Affiliations

    • Dako A/S, Glostrup, Denmark
    • ,
  • Susanne Møller

      Affiliations

    • Danish Breast Cancer Cooperative Group (DBCG) Registry, Copenhagen, Denmark
    • ,
  • Andreas Schønau

      Affiliations

    • Dako A/S, Glostrup, Denmark
    • ,
  • Eva Balslev

      Affiliations

    • Department of Pathology, Herlev University Hospital, Herlev, Denmark
    • ,
  • Ann S. Knoop

      Affiliations

    • Department of Oncology, Odense University Hospital, Odense, Denmark
    • ,
  • Bent Ejlertsen

      Affiliations

    • Danish Breast Cancer Cooperative Group (DBCG) Registry, Copenhagen, Denmark
    • Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Received 2 September 2009 ,Revised 10 November 2009 ,Accepted 11 November 2009.

References 

  1. Albertson DG. Gene amplification in cancer. Trends Genet. 2006;22(8):447–455
  2. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat. Genet. 2003;34(4):369–376
  3. Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc. Natl. Acad. Sci. USA. 1983;80(6):1707–1711
  4. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res. Treat. 2007;106(2):181–189
  5. Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J. Clin. Oncol. 2008;26(31):5027–5035
  6. Bouchalova K, Trojanec R, Kolar Z, Cwiertka K, Cernakova I, Mihal V, et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma. 2006;53(5):393–401
  7. Corzo C, Bellosillo B, Corominas JM, Salido M, Coll MD, Serrano S, et al. Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis. Tumour Biol. 2007;28(4):221–228
  8. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, et al HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002;8(5):1107–1116
  9. Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, et al Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur. J. Cancer. 2007;43(5):877–884
  10. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, et al Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J. Clin. Oncol. 2009;27(21):3430–3436
  11. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum. Pathol. 2005;36(4):348–356
  12. Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, et al Gene copy mapping of the ERBB2/ TOP2A region in breast cancer. Genes Chromosomes Cancer. 2004;40(1):19–31
  13. Järvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer. 1998;77(12):2267–2273
  14. Järvinen TAH, Tanner M, Bärlund M, Borg Å, Isola J. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer. Genes Chromosomes Cancer. 1999;26:142–150
  15. Järvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000;156(3):839–847
  16. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am. J. Pathol. 2003;163(5):1979–1984
  17. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005;23(30):7483–7490
  18. Koscielny S, Terrier P, Spielmann M, Delarue JC. Prognostic importance of low c-erbB2 expression in breast tumors. J. Natl. Cancer Inst. 1998;90(9):712
  19. Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, et al. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Taiwan J. Obstet. Gynecol. 2007;46(2):146–151
  20. Kuwahara Y, Tanabe C, Ikeuchi T, Aoyagi K, Nishigaki M, Sakamoto H, et al. Alternative mechanisms of gene amplification in human cancers. Genes Chromosomes Cancer. 2004;41(2):125–132
  21. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 2004;83(3):249–289
  22. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer. 2008;99(8):1296–1301
  23. McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics. 1941;26(2):234–282
  24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 2005;97(16):1180–1184
  25. Myllykangas S, Knuutila S. Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett. 2006;232(1):79–89
  26. Narayanan V, Mieczkowski PA, Kim HM, Petes TD, Lobachev KS. The pattern of gene amplification is determined by the chromosomal location of hairpin-capped breaks. Cell. 2006;125(7):1283–1296
  27. Nielsen KV, Müller S, Poulsen TS, Gabs S, Schonau A. Combined use of PNA and DNA for fluorescence in situ hybridization (FISH). In:  Nielsen PE editors. Peptide Nucleic Acids: Protocols and Applications. second ed. Norfolk: Horizon Bioscience; 2004;p. 227–260
  28. Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knoop A, Knudsen H, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 2008;47(4):725–734
  29. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 2009;101(9):615–618
  30. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004;43(1):35–42
  31. Pandis N, Teixeira MR, Adeyinka A, Rizou H, Bardi G, Mertens F, et al Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes Cancer. 1998;22(2):122–129
  32. Pauletti G, Lai E, Attardi G. Early appearance and long-term persistence of the submicroscopic extrachromosomal elements (amplisomes) containing the amplified DHFR genes in human cell lines. Proc. Natl. Acad. Sci. USA. 1990;87(8):2955–2959
  33. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 2008;26(5):736–744
  34. Rogalla P, Helbig R, Drieschner N, Flohr AM, Krohn M, Bullerdiek J. Molecular-cytogenetic analysis of fragmentation of chromosome 17 in the breast cancer cell line EFM-19. Anticancer Res. 2002;22(4):1987–1992
  35. Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc. Natl. Acad. Sci. USA. 2000;97(14):7921–7926
  36. Slamon DJ, Press MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J. Natl. Cancer Inst. 2009;101(9):615–618
  37. Stark GR, Debatisse M, Giulotto E, Wahl GM. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell. 1989;57(6):901–908
  38. Tanaka H, Yao MC. Palindromic gene amplification—an evolutionarily conserved role for DNA inverted repeats in the genome. Nat. Rev. Cancer. 2009;9(3):216–224
  39. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 2006;24(16):2428–2436
  40. Van Roy N, Vandesompele J, Menten B, Nilsson H, De Smet E, Rocchi M, et al. Translocation-excision-deletion-amplification mechanism leading to nonsyntenic coamplification of MYC and ATBF1. Genes Chromosomes Cancer. 2006;45(2):107–117
  41. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007;25(1):118–145

PII: S1574-7891(09)00138-0

doi: 10.1016/j.molonc.2009.11.001

Molecular Oncology
Volume 4, Issue 2 , Pages 161-168 , April 2010

Article Tools

* Image Usage & Resolution